This study examines the use of physiologically based pharmacokinetic (PBPK) models for inferring exposure when the number of biomarker observations per individual is limited, as commonly occurs in population exposure surveys. The trade-off between sampling multiple biomarkers at a specific time versus fewer biomarkers at multiple time points was investigated, using a simulation-based approach based on a revised and updated chlorpyrifos PBPK model originally published. Two routes of exposure, oral and dermal, were studied as were varying levels of analytic measurement error. It is found that adding an additional biomarker at a given time point adds substantial additional information to the analysis, although not as much as the addition of another sampling time. Furthermore, the precision of the estimates of exposed dose scaled approximately with the analytic precision of the biomarker measurement. For acute exposure scenarios such as those considered here, the results of this study suggest that the number of biomarkers can be balanced against the number of sampling times to obtain the most efficient estimator after consideration of cost, intrusiveness, and other relevant factors.
Introduction
The use of biomarker data to quantitatively infer aspects of the associated exposure has been a long-time research area of interest (Henderson, 1995; Needham et al., 1995) . This quantitative inference can be performed in a sophisticated manner using physiologically based pharmacokinetic (PBPK) models. These models introduce multiple physiological compartments to describe pharmacokinetics of a compound to which animals or people are exposed and are most commonly used to make predictions about the time course of location and disposition of metabolites and biomarkers of exposure (Hayes, 2001; Klaassen, 2001; Reddy et al., 2005) . Use of the models to instead infer exposure is sometimes referred to as the inverse approach (Georgopoulos et al., 1994) , and this is the approach of interest in this paper.
Of particular interest is the use of PBPK models to make inferences about environmental exposure scenarios for biomarker data collected in population-based studies. Although population data sets typically contain information on many individuals and so are quite large, they tend to contain relatively little information per individual regarding specific parent compound exposures. For a given individual, there are usually only one or two measurements collected of a particular biomarker, and environmental concentration measurements, when collected, usually lack the necessary activity information to develop the aggregate exposure profile. Reasons for this limited amount of information relate to effort and, more directly, expense. For a single biomarker, the expense and difficulty of collecting multiple days worth of readings are in many cases prohibitive.
The development of usable PBPK models for chemicals of interest allows greater sampling flexibility by allowing analysis of a wider set of biomarkers and combination of biomarkers. For example, the same compound can be considered a different biomarker when measured in both blood and urine. The availability of multiple biomarkers then leads to a trade-off in the design of studies: is it more efficient to sample fewer biomarkers over multiple time points or more biomarkers at a single time point? To our knowledge, the benefits of multiple biomarker readings for inference of exposure using PBPK models have not previously been systematically investigated. This question was addressed here using a simulation-based inverse PBPK approach together with a model for the commonly surveyed organophosphorous (OP) insecticide chlorpyrifos (CPF) .
Another characteristic of population exposure inference is that the exposure scenarios can be complex, with multiple possible routes and time variability of exposure. This study examined the inverse inference of both dermal and oral exposure using biomarker measurements resulting from what might be described as an acute environmental exposure scenario. This scenario is of a high-level one-time exposure where exposure by one route dominates allowing the other routes to be ignored. Thus the scenario considered is simpler than most environmental exposure scenarios, although results obtained from these studies may provide some guidance when considering more general scenarios.
Among non-insecticides, earlier work on the inverse analysis of exposure models includes Wallace et al. (1993) , where linear pharmacokinetic models were developed for use in estimating personal inhalation exposures to six volatile organic chemicals, and McKone (1993) , where a PBPK approach was taken for evaluation of experimentally measured ratios of chloroform concentrations in air and breath to tap water concentrations. Georgopoulos et al. (1994) used PBPK models and a likelihood approach to estimate short-term dermal and oral exposures to chloroform using both experimental and simulated data. Experimental data consisted of combined dermal and inhalation exposure in a swimming pool and of inhalation exposure only in a shower chamber. It was found that estimates were approximately within a factor of two of the experimental exposures, whereas they were typically within around 20% of the known values for simulated data. Furthermore, it was often found that it was possible to closely allocate the absorbed dose between the two routes. A later study by Roy and Georgopoulos (1998) used a PBPK model and a simulationbased approach to study a long-term 2-week exposure to benzene. Likelihood analysis of simulated data showed that with collection of six exhaled breath concentrations spaced 1 h apart and starting 12 h after the termination of a variety of exposure scenarios, they were typically able to estimate cumulative exposure to within 40% of its true value. This level of precision was possible due to the sequestering of benzene within the slowly perfused fat compartment of the PBPK model. In Sohn et al. (2004) , exposure inference was made using a PBPK model and a data set consisting of up to 14 venous blood measurements from samples collected from each of eight adult males exposed to inhalation of trichloroethylene in an enclosed chamber for 240 min. Adopting a Bayesian approach, they inferred the timing of onset, the duration, and the concentration of exposure to trichloroethylene. More recently, the work of Tan et al. (2006) integrated estimates of population pharmacokinetic variability in a PBPK model and patterns of water use to reconstruct exposures to chloroform and corresponding water concentrations. These methods have been extended to evaluate other trihalomethanes (Tan et al., 2007) .
Among the pesticides, Rigas et al. (2001) used a simple onecompartment pharmacokinetic model for CPF and data consisting of up to three exposure measurements per person of urine concentrations of biomarker 3,5,6-trichloro-2-pyridinol (TCP) to estimate the magnitude and timing of dose. Individuals of interest were identified by having both high measured urine concentrations of TCP and, indicated proximity to recent pesticide application on the survey questionnaire. The paper also provided a comparison of background steady-state dose rate as estimated by their model and more directly by environmental media measurements.
CPF was selected as the parent compound of interest for the present study because of its importance in various major surveys of interest, the availability in the literature of substantial pharmacokinetic and metabolic data, and a published PBPK model. Surveys that have collected CPF data include the CDC's National Health and Nutrition Examination Survey (NHANES; Barr et al., 2004 Barr et al., , 2005 ), EPA's National Human Exposure Assessment Survey (NHEXAS; Egeghy et al., 2005) , and EPA's Children's Total Exposure to Persistent Pesticide and Other Persistent Pollutants (CTEPP; Morgan et al., 2005) . These surveys frequently detected TCP (a metabolite derived from CPF or CPF methyl) in urine from volunteers participating in CTEPP, NHANES, and NHEXAS, and also the two dialkylphosphates, diethylphosphate (DEP) and diethylthiophosphate (DETP) that can be derived from exposure to CPF, CPF methyl, and other OPs. Although CPF is no longer approved in the United States for residential applications, it remains an agricultural OP insecticide of widespread use (USDHHS, 1997; DowAgroSciences, 2007) .
The metabolism of CPF proceeds though cytochrome P450 and paraoxonase 1 (PON1) pathways. Figure 1 (Timchalk et al., 2002a) illustrates this metabolism, including the generation of major metabolites CPF-oxon, TCP, DEP, and DETP. Two routes are indicated (1) the activation of CPF via cytochrome P450 to produce CPF-oxon, the putative toxic metabolite, followed by further metabolism to DEP and TCP and (2) the detoxification of CPF via conversation to DETP and TCP.
Methods
The following steps were taken in performing the analyses described in this paper. First, the Timchalk et al. (2002b) CPF PBPK model was modified to include all five biomarkers of interest here: TCP in urine and blood, CPF in blood, DEP in urine, and DETP in urine. The existing and new parameter values of the PBPK model were updated after review of the literature. Second, for the dermal and oral exposure scenarios of interest, a variety of biomarker sampling designs were specified, allowing for varying combinations of biomarkers and measurement times. Exposure scenarios were then simulated with time course measurements sampled according to each of the designs, considering either a typical or a high level of measurement error. Maximum likelihood methods were used to obtain estimates of initial exposure concentrations, and these estimates were then compared to the known exposures to determine the influence of the sampling design on estimation error. These steps are now described in greater detail.
PBPK Modeling
The PBPK model described in this study is a modified version of the one that was developed for CPF and its metabolites CPF-oxon and TCP in Timchalk et al. (2002b) . This model has multiple compartments defined for CPF and CPF-oxon and single compartment for TCP. It includes both dermal and oral dietary routes of exposure.
In this study, the Timchalk model was extended to include the CPF nonspecific metabolites, DEP and DETP. Following the approach taken for TCP, each of these compounds was modeled using a single compartment, with metabolic processes described according to Michaelis-Menten kinetics. The modified model is shown schematically in Figure 2 .
All of the PBPK parameter values given in the Timchalk paper were reviewed and parameter values for the modified model were then (1) taken from the Timchalk paper, (2) obtained from the literature, or (3) estimated by maximum likelihood. Parameters estimated by likelihood consisted of all those previously estimated in the Timchalk paper using the Nolan et al. (1984) data. The Nolan data set gives timecourse readings of TCP in blood and urine after separate oral and dermal exposure in human volunteers. A complete list of final PBPK model parameters and references is given in Table 1 . Parameters for the PD portion of the model were not altered and can be found in Table 2 of the Timchalk paper.
The commercial software package acslXtreme s (AEgis Technologies Group Inc.) was used for model development, parameter estimation, and simulation. The PBPK model equations, both ordinary differential and algebraic, can be found in the Appendix.
Exposure Scenarios
The exposure scenarios considered here consist of a onetime exposure to CPF either dermally or orally. The oral exposure of CPF was set to be 500 mg/kg CPF, a level equal to that used in Nolan et al. (1984) . The dermal exposure was 5000 mg/kg applied to an area of 100 cm 2 , with washing occurring 5 h post-application. This washing occurs an hour before the first sample reading and represents the effort to remove the compound after use. In occupational settings, which could be analogous to a high-level non-recurring event, the exposure duration typically ranges from 2 to 8 h (Nash et al., 1982) .
Sampling of blood and/or urine was assumed to occur at 6, 18, 42, and 66 h post-exposure with up to five biomarkers measured in each sample. These sampling times could represent a single sample 6 h after a 1400 hours exposure, followed by additional morning samples at 0800 hours for the following 3 days. For urine samples, bladder voiding occurred at hours 0, 6, 10, 18, 36, 42, 58, and 66 corresponding to the collected sample and void previous to that.
The four main sample designs were thus One sample collection time at 6 h post-exposure. Two sample collection times at 6 and 18 h post-exposure. Three sample collection times at 6, 18 and 42 h postexposure. Four sample collection times at 6, 18, 42, and 66 h post-exposure.
The combinations of biomarkers sampled and analyzed were Only TCP in urine. Both TCP in urine and in blood. Only blood biomarkers: both TCP in blood and CPF in blood. TCP in urine, TCP in blood, and CPF in blood. Only urine biomarkers: TCP in urine, DEP in urine, and DETP in urine. All five biomarkers: TCP in urine and blood, CPF in blood, DEP in urine, and DETP in urine.
Blood measurements are in micromoles per liter, whereas urine measurements are in micromoles, providing the total accumulated in the compartment since the previous void.
Of the five biomarkers, DEP and DETP are nonspecific, possibly being the products of exposure to other OP insecticides, and TCP is a nonspecific biomarker when there is a potential for direct exposure to it (Wilson et al., 2003; Morgan et al., 2005) . For example, Morgan et al. (2005) found environmental levels of TCP in solid food in residences to be 12 times that of CPF. The scenario considered here, however, is that of a single high-level (acute) exposure of CPF with no other OP insecticides or metabolites of CPF substantially present.
Also considered were samples consisting of blood biomarkers at 6 h and urine biomarkers the next morning at 18 h (Ramsey and Andersen, 1984) . Percentage of body weight for slowly perfused tissues ¼ 82Àpercentage of body weight of fat+diaphragm+skin (Ramsey and Andersen, 1984). b This parameter is scaled in proportion to body weight raised to the threefourths power for intraspecies extrapolation (Andersen et al., 1987; Clewell et al., 1999) . c Cardiac output of rapidly perfused tissues ¼ 76Àcardiac output of liver+ brain (Ramsey and Andersen, 1984) . Cardiac output of slowly perfused tissues ¼ 24Àcardiac output of fat+diaphragm+skin (Ramsey and Andersen, 1984) . Maximum likelihood estimates (MLEs) as obtained using the Nolan et al. (1984) data. Estimates were obtained from a single fit to a data set containing both oral and dermal measurements. The value of the log-likelihood at the obtained maximum was À40.05. e It is assumed for this model the volume of distribution for TCP is the same as the volume of distribution for each DEP and DETP, and so these are all represented by the same parameter within the model. After an oral dose of CPF, the half-life for the dialkylphosphate metabolites (DEP and DETP) was 15.5 h. After a dermal dose of CPF, the half-life for the dialkylphosphate metabolites (DEP and DETP) was 30 h. For this model, it is assumed that the half-life for the dialkylphosphates, route specific, is the same as the half-life for each DEP and DETP. The arithmetic mean of the two half-lives, oral and dermal, was taken to calculate the urinary elimination rates for DEP and DETP. After an oral exposure to diazinon, which has similar chemical and physical properties to CPF, the unhydrolysed proportion of dose excreted as urinary dialkylphosphate metabolites (DEP and DETP) was 66%. For this model, it was assumed that this value is the fractional urine excretion (%) for each DEP and DETP.
Reconstructing exposures from small samples: PBPK models and multiple biomarkersafter exposure. Two sets of biomarkers were sampled, either TCP in both blood and urine, or all blood biomarkers and all urine biomarkers.
For each combination of biomarkers and sampling times, a total of 100 simulated data sets were created. A PBPK time course was generated and then time-course data sets created by adjusting values at the sampled time points by a normally distributed random error. For m biomarkers and n time-course measurements, the simulated observation X ij is equal to 
Statistical Methods
Estimation of parameters is carried out using the method of maximum likelihood, where for the above model the likelihood function L can be written as: Nolan et al. (1984) data (see Table 1 ), or was one-dimensional for the exposure scenarios where only the initial exposure concentration was unknown.
Once an initial starting value Y 0 for Y has been chosen, maximization of the log-likelihood proceeds numerically for Y and s 1 2 ,y, s m 2 by an iterative two-step process whereby an optimization algorithm searches the Y space. Details can be found in the SIMUSOLV manual (Dow Chemical Co., 1990).
Evaluation of simulation output was carried out using two statistics: mean absolute percent error (MAPE) and mean relative bias (MRB). The MAPE for simulation estimateŝ y 1 ; . . . ;ŷ N is defined as:
and so gives a measure of average absolute error from the known true value y. The MRB is defined as
i À y y and will suggest whether the maximum likelihood estimator is biased, where an unbiased estimator will have an MRB near zero. Approximate margins of error and confidence intervals for the MAPE and MRE are found using the one-sample t-distribution approach at a 95% confidence level.
Results

PBPK Model Fitting and Analysis of Time-Course Output
Parameters of the modified Timchalk et al. (2002b) model are given in Table 1 . A total of eight free parameters were obtained by fitting to the Nolan et al. (1984) data, four of which were specific to the oral exposure pathway (KaS, KaI, KsI, and Fa), one to the dermal exposure pathway (Kp), and three common to all exposure routes in the PBPK model (Ke TCP , Fu TCP , and the volume of distribution for Vd TCP , Vd DEP , and Vd DETP , using the constraint Vd TCP ¼ Vd DEP ¼ Vd DETP ). Comparison of PBPK model time-course output to the Nolan et al. (1984) data is provided in Figure 3 . In the figure, each of the oral and dermal exposure data sets is plotted for both TCP measured in blood and urine. The model appears to fit the data reasonably well over the period from 0 to 50 h, after which for all time series some under-fitting of the data occurs.
Time-course plots for the CPF model with dermal, ingestion, and combined exposure routes are provided in Figure 4 . Ingestion exposure is of a single bolus dose of 500 mg/kg, while dermal exposure is of 5000 mg/kg applied for a 5-h Maximum observed concentration over time course of study simulations.
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period. Time-course readings begin at the start of exposure. Profiles among one-compartment biomarkers (urinary TCP, urinary DEP, urinary DETP, and blood TCP) are all of similar shape, with a sharp increase for oral exposure, and a more gradual increase for dermal. In contrast, the blood CPF series show sharp increase for dermal exposure, up to the 5 h wash after which blood concentration declines rapidly. To better characterize the behavior of the PBPK model, units for urine are micromoles per hour, and so plotted urine values are the instantaneous rate of elimination of given biomarkers from the one-compartment model. Linear metabolism in the CPF model is important because environmentally relevant concentrations usually exhibit non-saturable metabolism. Metabolic steps with MichaelisMenten metabolism are described by
where V max and K m,x are the Michaelis-Menten reaction parameters, c v,x is the substrate concentration, and for the CPF model x represents liver or blood. The model can be considered to be approximately linear provided that c v,x 5K m,x , with c v,x being no more than 5% of K m,x (Roy and Georgopoulos, 1998) . Table 2 provides maximum values of c v,x observed in time series for the oral and dermal scenarios considered here, and it can be seen that all values are well below 5% of K m,x . Thus, metabolism is well within the linear range.
Likelihood Analysis
Time-course simulations for each of the biomarker combinations and sampling times were used to obtain maximum likelihood estimates of exposed amount for both oral and dermal exposure scenarios at each of two levels of measurement error. A total of 100 simulated data sets were created for each of the sample designs.
MAPEs and margins of error for oral exposure simulations at 5% measurement error are provided in Table 3 for the four time periods of sampling and the six chosen biomarker combinations. The results provided in the table show that the MAPE tends to decrease as both sampling days and biomarkers are added to the model. Across biomarkers, with few exceptions, the MAPE estimates of Table 3 trended lower as the number of biomarkers increased. Pairwise comparison of MAPEs suggests that for adjacent counts of biomarkers (1-2, 2-3,y) MAPEs would typically not differ significantly, although if the comparison were made of more distant MAPEs they would be found to differ, with MAPEs for samples with more biomarkers being smaller. Furthermore, this trend becomes more pronounced as the number of time-course measurements increases. Across time points the MAPE estimates trended lower as the number of time-course measurements increased. This trend was stronger than that for the addition of biomarkers; consider for example the comparison of multiple TCP urine-only measurements against multiple biomarkers at a single 6 h post-exposure time point. Table 4 gives MAPEs and their margins of error for oral exposure simulations at the 25% relative measurement error. Again, MAPE is seen to decrease as both biomarkers and time-course measurements increase. The magnitude of increase in the MAPE over the 5% simulations is close to the factor of five expected from scaling of the measurement error. This is illustrated in Figure 5 , which plots the sample standard deviations of the dose estimates for each of the MAPEs and margins of error for simulations of the dermal exposure route at 5% measurement error are given in Table 5 . The observed trends are the same as those in the corresponding oral exposure, and comparison of MAPEs shows that margins of error would in almost all cases give overlapping confidence intervals, not giving significant differences in pairwise comparison. Cases where margins of error do not overlap the MAPEs can be shown to be not significantly different after accounting for the multiple comparisons. Table 6 gives MAPEs and margins of error for simulations of the dermal exposure route at 25% measurement error. The same trends are seen in comparison to the 5% measurement error results as were found for the oral exposure route Table 3 . Oral bolus dose exposure mean absolute percent errors (MAPEs) and margins of error for various biomarker and sampling combinations at 5% measurement error.
Biomarkers sampled
Hours post-exposure 6 h 6, 18 h 6, 18, 32 h 6, 18, 32, 56 h MAPE ME MAPE ME MAPE ME MAPE ME simulations. Similarly, the comparison of the oral simulation results at 25% measurement error suggests the same trends as were noted between the two 5% measurement error tables.
MRB plots for the oral exposure simulations at 5% measurement error are provided in Figure 6 and show no evidence of bias in the maximum likelihood estimators. The plot also provides an illustration of the increasing precision of the estimates as the number of biomarkers and time-course measurements increase.
Simulation results for the sampling of blood biomarkers in the evening and urine biomarkers in the morning are provided in Table 7 . Two cases were considered: (1) only TCP in blood and urine, and (2) all possible biomarkers. As with previous simulations, an increase in the number of biomarkers decreased the MAPE, with the all biomarker case nearly reducing it by half. In comparison to Tables 3-6, sampling at two time points with differing biomarkers appears to have slightly higher MAPE as compared to sampling at two time points with the same biomarker, although is not significant considering the multiple comparisons.
Discussion
The use of multiple biomarkers to assess exposure was described in Henderson (1995) , where the goal was to find multiple biomarkers of varying half-lives so as to distinguish among different possible exposure scenarios. Our goal in using multiple biomarkers in this study has been slightly different: for simple well-defined exposure scenarios and small sample sizes, we have explored the trade-offs between sampling multiple time periods versus multiple biomarkers. These trade-offs are a research question of interest since the sampling of a single biomarker over multiple times may be much more difficult and expensive than the collection of multiple biomarkers at a single sampling event in general population studies.
The results of this study show that for the exposure scenarios considered here, sampling either more biomarkers per time point or more time points per biomarker increases the information available for the analysis, improving estimator precision. Furthermore, it was also observed that additional time points tended to be somewhat more effective in reducing the MAPE than additional biomarkers. Thus, all else being equal, an additional time point appears to benefit the analysis more than an additional biomarker. This conclusion is, however, subject to real-world concerns such as cost, intrusiveness, and the potential for additional exposures between time measurements.
Within this study, the dermal and oral route of exposure showed similar levels of error in estimating exposed concentration. This is to an extent expected given that the model fitting in each case is structurally very similar F multiplicative errors added to points on up to five deterministic time-course curves, all of which are functions of a single unknown dose parameter and all of which equal zero at time of exposure. Under these assumptions, the performance of the methods is not surprisingly similar.
The MAPE comparisons also illustrate the pronounced effect that an increased measurement error had on the ability to reconstruct exposures. A 25% relative measurement error greatly increases the MAPE over the 5% case for a given sample design. For example, not one of the MAPEs observed at 25% measurement error was smaller than that observed at only a single time-course reading of TCP in urine at 5% --even the five biomarkers, four time-course reading values were larger. Thus inference for these scenarios benefits greatly from the use of precise analytic equipment.
For the exposure scenarios considered here, the standard deviation of the dose estimates increased roughly in proportion to increases in measurement error. Since the dose estimator is a nonlinear function of the time-course measurements an exact relationship is not required. This direct effect does, however, again illustrate the importance of analytically precise methods for the inference of exposed dose.
One of the sampling designs considered in this study was the collection of blood at 6 h post-exposure and urine at 18 h post-exposure. This sample design was roughly the same in performance to the same biomarkers all sampled on a single day, for example the oral exposure MAPE of blood followed by urine sampling of TCP was 3.77 (Table 3) , whereas both sampled on the same day was 4.3 (Table 7) . Sampling different biomarkers on separate days will add costs associated with sample collection. A potential topic for future research is the selection of optimal sampling times for the best estimation of the exposure concentration. Choice of sampling times for discrimination among multiple routes of exposure was addressed in the simulation of Georgopoulos et al. (1994) , where they found that to determine whether oral or dermal routes of exposure to chloroform were operating, observations at 10 and 15 min post-exposure were much more informative than those collected at 20 min and onwards.
A limitation of the analyses performed here is that they did not allow for population-level variability in the PBPK model parameters, and so the observations being simulated were all derived from individuals with the same PBPK parameter values. This assumption is not realistic in practice, and so a future research question about the estimation of exposure scenario parameters is the influence of the individual variation on the results. This problem might be addressed in future analyses by the extension of the model to a Bayesian framework (Gelman et al., 1996; Wakefield, 1996) .
The exposure scenarios considered here have been referred to as acute environmental exposure scenarios, defined as a one-time exposure well in excess of typical environmental levels. Use of these scenarios has simplified efforts to study the sampling design issues associated with PBPK models and small samples. However, these scenarios may also have some interest in practice, particularly as they relate to a single event at lower exposures such as might occur in the workplace by occupational activity, or by activity in treated areas.
An area of larger interest for biomarker interpretation is the realm of environmental exposures (NRC, 2006). These Reconstructing exposures from small samples: PBPK models and multiple biomarkersexposures are characterized by having multiple routes operating simultaneously at low and variable toxicant concentrations among the media that contribute to the routes. For CPF, the Maryland NHEXAS data (Pang et al., 2002) support the combined operation of both inhalation and ingestion, while other routes can be largely ignored. The complexity and temporal variability of real-world environmental exposure scenarios provide challenging research areas in the extension of the modeling frameworks given here. However, results from studies with simple scenarios such as described in this paper can offer guidance for sample design with more complicated scenarios. 
